Literature DB >> 6802161

Valproic acid and diazepam interaction in vivo.

S Dhillon, A Richens.   

Abstract

1 The effect of oral administration of sodium valproate (1500 mg daily) on the distribution and elimination kinetics of intravenously administered diazepam in six healthy volunteers has been studied. 2 During valproate administration the unbound fraction of diazepam in serum increased approximately two fold. This was accompanied by a significant increase in apparent volume of distribution and plasma clearance of diazepam. 3 There was a positive correlation between the change in free fraction and the increase in both apparent volume of distribution and plasma clearance of the drug. 4 The concentration of unbound diazepam in serum (calculated from the percent free diazepam and total serum concentration) was significantly higher during valproate administration. Both the intrinsic clearance and volume of distribution of unbound drug were significantly reduced. 5 Mean serum N-desmethyldiazepam levels were significantly lower during valproate coadministration. 6 These results suggest that valproic acid displaces diazepam from plasma protein binding sites and inhibits its metabolism.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6802161      PMCID: PMC1402061          DOI: 10.1111/j.1365-2125.1982.tb01421.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  28 in total

1.  The displacing effect of a fatty acid on the binding of diazepam to human serum albumin.

Authors:  E Tsutsumi; T Inaba; W A Mahon
Journal:  Biochem Pharmacol       Date:  1975-07-15       Impact factor: 5.858

2.  The protein binding of diazepam and N-demethyldiazepam in patients with poor renal function.

Authors:  L Kangas; J Kanto; J Forsström; E Iisalo
Journal:  Clin Nephrol       Date:  1976-03       Impact factor: 0.975

3.  Plasma protein binding of diazepam and tolbutamide in chronic alcoholics.

Authors:  J J Thiessen; E M Sellers; P Denbeigh; L Dolman
Journal:  J Clin Pharmacol       Date:  1976-07       Impact factor: 3.126

4.  Rapid micro-method for the measurement of diazepam and desmethyldiazepam in blood plasma by gas-liquid chromatography.

Authors:  D M Rutherford
Journal:  J Chromatogr       Date:  1977-07-21

5.  Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution.

Authors:  P K Lunde; A Rane; S J Yaffe; L Lund; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1970 Nov-Dec       Impact factor: 6.875

6.  Pharmacokinetics of diazepam in dogs, mice and humans.

Authors:  E van der Klejin; J M van Rossum; E T Muskens; N V Rijntjes
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1971

7.  Circular dichroism studies on the inhibiting effect of oleic acid on the binding of diazepam to human serum albumin.

Authors:  T Sjödin
Journal:  Biochem Pharmacol       Date:  1977-11-15       Impact factor: 5.858

8.  The effects of age and liver disease on the disposition and elimination of diazepam in adult man.

Authors:  U Klotz; G R Avant; A Hoyumpa; S Schenker; G R Wilkinson
Journal:  J Clin Invest       Date:  1975-02       Impact factor: 14.808

9.  Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat.

Authors:  U Klotz; K H Antonin; P R Bieck
Journal:  J Pharmacol Exp Ther       Date:  1976-10       Impact factor: 4.030

10.  Determination of the anticonvulsant drug--dipropyl acetate (Epilim) in human plasma by gas chromatography.

Authors:  H U-Schulz; P A Toseland
Journal:  Ann Clin Biochem       Date:  1977-07       Impact factor: 2.057

View more
  10 in total

1.  In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).

Authors:  X Wen; J S Wang; K T Kivistö; P J Neuvonen; J T Backman
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

Review 2.  Protein binding drug displacement interactions fact or fiction?

Authors:  J J MacKichan
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

3.  Evaluation of the pharmacokinetic interaction between diazepam and ACC-9653 (a phenytoin prodrug) in healthy male volunteers.

Authors:  E K Hussey; G E Dukes; J A Messenheimer; K L Brouwer; K H Donn; T F Krol; L J Hak
Journal:  Pharm Res       Date:  1990-11       Impact factor: 4.200

4.  In vitro changes in the proportion of protein-unbound-free propofol induced by valproate.

Authors:  Minako Ishii-Maruhama; Hitoshi Higuchi; Mai Nakanou; Yuka Honda-Wakasugi; Akiko Yabuki-Kawase; Shigeru Maeda; Takuya Miyawaki
Journal:  J Anesth       Date:  2018-07-30       Impact factor: 2.078

5.  Therapeutic drug monitoring.

Authors:  N Buchanan
Journal:  Indian J Pediatr       Date:  1986 Mar-Apr       Impact factor: 1.967

Review 6.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 7.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

8.  Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients.

Authors:  A Tartara; C A Galimberti; R Manni; L Parietti; C Zucca; H Baasch; L Caresia; W Mück; N Barzaghi; G Gatti
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

Review 9.  Antiepileptic drugs. A review of clinically significant drug interactions.

Authors:  P N Patsalos; J S Duncan
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

10.  Contribution of baicalin on the plasma protein binding displacement and CYP3A activity inhibition to the pharmacokinetic changes of nifedipine in rats in vivo and in vitro.

Authors:  Zhen-Yu Cheng; Xin Tian; Jie Gao; Hong-Meng Li; Lin-Jing Jia; Hai-Ling Qiao
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.